FILTER
LATEST ARTICLES
Serialization Regulations Put Packaging Into the Limelight
April 24, 2019
Changing serialization requirements represent an opportunity for packaging companies that are looking to add value for their clients.
Breaking Down Drug Pricing
April 01, 2019
The U.S. biopharmaceuticals industry continues to grapple with the perennial issue of drug pricing.
Exploration in B.C., Yukon and Canada’s North
March 27, 2019
The convergence of government commitment, improved market conditions and increased industry collaboration usher in an era of reconciliation for B.C. miners.
Taking Care of All Stakeholders
March 27, 2019
Environmental care, safe labor conditions and government and community relations: companies need to implement a 360-degree strategy for sustainability.
Sustainability: a Comprehensive Look
March 27, 2019
The ‘S’ word is a wide-reaching concept that demands a joint effort on many fronts by governments, the industry, and the wider population.
Peru’s Mining Industry Grows on Autopilot
February 27, 2019
The country’s mining sector isolates itself from the political noise to continue promoting its mineral production
Innovative Mining Solutions
February 27, 2019
Québec’s mining service industry is at the forefront of the evolution towards the modern mine
B.C. Mining Enters an Era of Reconciliation
February 13, 2019
True cohesion between government, Indigenous groups and the sector is the priority.
Metals and Materials of the Future
February 13, 2019
Lithium and vanadium projects are attracting substantial investment.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
